Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 620-625

  Tickenbrock, Lara ^a,g   Klein, Hans Ulrich ^a   Trento, Cristina ^a   Hascher, Antje ^a   Göllner, Stefanie ^a   Bäumer, Nicole ^a   Kuss, Robert ^a   Agrawal, Shuchi ^a   Bug, Gesine ^b   Serve, Hubert ^b   Thiede, Christian ^c   Ehninger, Gerhard ^c   Stadt, Udo zur ^d   McClelland, Michael ^e   Wang, Yipeng ^e   Becker, Anke ^f   Koschmieder, Steffen ^a   Berdel, Wolfgang E ^a   Dugas, Martin ^a   Müller Tidow, Carsten ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e SIDNEY KIMMEL CANCER CENTER   (United States)

^f UNIVERSITY OF FREIBURG   (Germany)

^g Hamm Lippstadt University of Applied Science   (Germany)

Author keywords

AML; ChIP; HDAC

Indexed keywords

HISTONE DEACETYLASE 1;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN BINDING; ARTICLE; CANCER SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIGENETICS; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; SUPPORT VECTOR MACHINE; TRANSCRIPTION REGULATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHROMATIN; FEMALE; HEMATOPOIESIS; HISTONE DEACETYLASE 1; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79954592316     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.11.006     Document Type: Article

References (33)

1. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1(December (3)):194-202.
2. Allfrey V.G., Faulkner R., Mirsky A.E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 1964, 51(May):786-794.
3. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370(March (Pt 3)):737-749.
4. Taunton J., Hassig C.A., Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996, 272(April (5260)):408-411.
5. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363(December):15-23.
6. Cress W.D., Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000, 184(July (1)):1-16.
7. Mahlknecht U., Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000, 6(August (8)):623-644.
8. Timmermann S., Lehrmann H., Polesskaya A., Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001, 58(May (5-6)):728-736.
9. Melnick A., Licht J.D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002, 9(July (4)):322-332.
10. Lin R.J., Nagy L., Inoue S., Shao W., Miller W.H., Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391(February (6669)):811-814.
11. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391(February (6669)):815-818.
12. Hoemme C., Peerzada A., Behre G., Wang Y., McClelland M., Nieselt K., et al. Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 2008, 111(March (5)):2887-2895.
13. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998, 95(September (18)):10860-10865.
14. Bug G., Schwarz K., Schoch C., Kampfmann M., Henschler R., Hoelzer D., et al. Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. Haematologica 2007, 92(April (4)):542-545.
15. Bug G., Gul H., Schwarz K., Pfeifer H., Kampfmann M., Zheng X., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005, 65(April (7)):2537-2541.
16. Munster P.N., Troso-Sandoval T., Rosen N., Rifkind R., Marks P.A., Richon V.M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001, 61(December (23)):8492-8497.
17. Han J.W., Ahn S.H., Park S.H., Wang S.Y., Bae G.U., Seo D.W., et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 2000, 60(November (21)):6068-6074.
18. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1(April (4)):287-299.
19. Hoshikawa Y., Kwon H.J., Yoshida M., Horinouchi S., Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 1994, 214(September (1)):189-197.
20. Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T., et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 1999, 13(September (9)):1316-1324.
21. Johnstone R.W., Licht J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell 2003, 4(July (1)):13-18.
22. Tickenbrock L., Schwable J., Wiedehage M., Steffen B., Sargin B., Choudhary C., et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 2005, (January).
23. Muller-Tidow C., Steffen B., Cauvet T., Tickenbrock L., Ji P., Diederichs S., et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004, 24(April (7)):2890-2904.
24. Huber W., von Heydebreck A., Sultmann H., Poustka A., Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18(Suppl. 1):S96-S104.
25. Goeman J.J., van de Geer S.A., de Kort F., van Houwelingen H.C. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004, 20(January (1)):93-99.
26. Smyth G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. [article 3].
27. Benjamini Y., Drai D., Elmer G., Kafkafi N., Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001, 125(November (1-2)):279-284.
28. Thomas P.D., Campbell M.J., Kejariwal A., Mi H., Karlak B., Daverman R., et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003, 13(September (9)):2129-2141.
29. Cortes C., Vapnik V. Support-vector networks. Mach Learn 1995, 20(3):197-207.
30. Bair E., Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004, 2(April (4)):E108.
31. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5(10):R80.
32. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(March (11)):1148-1159.
33. Barbetti V., Gozzini A., Rovida E., Morandi A., Spinelli E., Fossati G., et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008, 27(March (12)):1767-1778.